2-Chloro-4-morpholinothieno[3,2-d]pyrimidine-6-carbaldehyde

Catalog No. :
ACDRWP068
CAS No. :
885618-31-5
Molecular Formula :
C11H10ClN3O2S
Molecular Weight :
283.74

IUPAC Name:2-chloro-4-morpholinothieno[3,2-d]pyrimidine-6-carbaldehyde

2-Chloro-4-morpholinothieno[3,2-d]pyrimidine-6-carbaldehyde structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
250mg95%$236.00Login to see priceIn stockInquiry
1g95%$466.00Login to see priceIn stockInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name2-Chloro-4-morpholinothieno[3,2-d]pyrimidine-6-carbaldehyde
IUPAC Name2-chloro-4-morpholinothieno[3,2-d]pyrimidine-6-carbaldehyde
MDL No.MFCD11520864
Molecular FormulaC11H10ClN3O2S
Molecular Weight283.74
SMILESClC1=NC3=C(C(=N1)N2CCOCC2)SC(=C3)C=O
InChI KeyPFAKZIZFIXKDFP-UHFFFAOYSA-N
SynonymMFCD11520864 | BCP34669 | A861739 | 2-Chloro-4-morpholin-4-yl-thieno[3,2-d]pyrimidine-6-carbaldehyde | 2-chloro-4-morpholin-4-ylthieno[3,2-d]pyrimidine-6-carbaldehyde | 2-Chloro4morpholin-4-yl-thieno[3,2-d]pyrimidine-6carbaldehyde | 2-Chloro-4-morpholinot
CAS No.885618-31-5
PubChem CID45789985

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H332-H335
Precautionary Statement(s)
P280-P305+P351+P338-P310

Synthetic Route by SureRoute

1. ACDRWP068 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACRMZL504 route compound structure diagram
    ACRMZL50416234-15-4 In Stock
  2. Then
  3. ACDRWP068 route product structure diagram
    ACDRWP068885618-31-5 In Stock
Inquiry

2. ACDRWP068 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACRMZL504 route compound structure diagram
    ACRMZL50416234-15-4 In Stock
  4. Then
  5. ACDRWP068 route product structure diagram
    ACDRWP068885618-31-5 In Stock
Inquiry

Comments (0)